CLChanghyun Lee

Changhyun Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Changhyun Lee has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Seung Hyeok Han

    Department of Internal Medicine and Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea

    5 shared publications
  • Curie Ahn

    Department of Internal Medicine, Seoul National University, Seoul, South Korea

    3 shared publications
  • Jung Tak Park

    Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, South Korea

    3 shared publications
  • Ki Heon Nam

    Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, South Korea; Division of Hospital Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

    3 shared publications
  • Sangmi Lee

    Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea

    3 shared publications
  • Tae-Hyun Yoo

    Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea

    3 shared publications

Latest Publications

  • Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD

    by Changhyun Lee, Jung Tak Park, Tae-Ik Chang, Ea Wha Kang, Ki Heon Nam, Young Su Joo, Su-Ah Sung, Yeong Hoon Kim, Dong-Wan Chae, Su Kyung Park, et al.


  • Open Access

    Low High‐Sensitivity C‐Reactive Protein Level in Korean Patients With Chronic Kidney Disease and Its Predictive Significance for Cardiovascular Events, Mortality, and Adverse Kidney Outcomes: Results From KNOW‐CKD

    by Changhyun Lee, Keun Hyung Park, Young Su Joo, Ki Heon Nam, Tae‐Ik Chang, Ea Wha Kang, Joongyub Lee, Yun Kyu Oh, Ji Yong Jung, Curie Ahn, et al.

    Background: Inflammation levels are lower in East Asians than in Western people. We studied the association between high‐sensitivity hs‐CRP (C‐reactive protein) and adverse outcomes in Korean patients with chronic kidney disease. Methods and Results: We included 2018 participants from the KNOW‐CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease) between April 2011 and February 2016. The primary outcome was a composite of extended major cardiovascular events (eMACE) or all‐cause mortality. The secondary end points were separate outcomes of eMACE, all‐cause death, and adverse kidney outcome. We also evaluated predictive ability of hs‐CRP for the primary outcome. The median hs‐CRP level was 0.60 mg/L. During the mean follow‐up of 3.9 years, there were 125 (6.2%) eMACEs and 80 (4.0%) deaths. In multivariable Cox analysis after adjustment of confounders, there was a graded association of hs‐CRP with the primary outcome. The hazard ratios for hs‐CRPs of 1.0 to 2.99 and ≥3.0 mg/L were 1.33 (95% CI, 0.87–2.03) and 2.08 (95% CI, 1.30–3.33) compared with the hs‐CRP of <1.0 mg/L. In secondary outcomes, this association was consistent for eMACE and all‐cause death; however, hs‐CRP was not associated with adverse kidney outcomes. Finally, prediction models failed to show improvement of predictive performance of hs‐CRP compared with conventional factors. Conclusions: In Korean patients with chronic kidney disease, the hs‐CRP level was low and significantly associated with higher risks of eMACEs and mortality. However, hs‐CRP did not associate with adverse kidney outcome, and the predictive performance of hs‐CRP was not strong. Registration: URL: http://www.clinicaltrials.gov ; Unique identifier: NCT01630486.


  • Smoking, Smoking Cessation, and Progression of Chronic Kidney Disease: Results From KNOW-CKD Study

    by Sangmi Lee, Shinchan Kang, Young Su Joo, Changhyun Lee, Ki Heon Nam, Hae-Ryong Yun, Jung Tak Park, Tae Ik Chang, Tae-Hyun Yoo, Soo Wan Kim, et al.

    Introduction: In patients with chronic kidney disease (CKD), studies investigating the association between smoking and deterioration of kidney function are scarce. Aims and Methods: We analyzed data for 1,951 patients with an estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m2 enrolled in the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD) from 2011 to 2016. Patients were categorized by smoking load. Primary outcome was a composite of a ≥50% reduction in eGFR, initiation of dialysis, or kidney transplantation. Results: There were 967 never-smokers and 369, 276, and 339 smokers who smoked <15, 15 to 29, ≥30 pack-years, respectively. During a mean follow-up of 3.0 years, the incidence rates (95% confidence interval [CI]) of the primary outcome were 54.3 (46.4–63.5), 46.9 (35.9–61.4), 69.2 (52.9–90.6), and 76.3 (60.7–96.0) events per 1,000 person-yr in never-, <15, 15 to 29, and ≥30 pack-year smokers. In cause-specific hazard model after adjustment of confounding factors, smokers were associated with 1.09 (0.73–1.63), 1.48 (1.00–2.18), and 1.94 (1.35–2.77) fold increased risk (95% CI) of primary outcome in <15, 15–29, and ≥30 pack-year smokers compared with never-smokers. The association of longer smoking duration with higher risk of CKD progression was evident particularly in patients with eGFR < 45 mL/min/1.73 m2 and proteinuria ≥ 1.0 g/g. In contrast, the risk of adverse kidney outcome decreased with longer smoking-free periods among former-smokers. Conclusions: These findings suggest potentially harmful effects of the degree of exposure to smoking on the progression of CKD. Implications: Among patients with CKD, there has been lack of studies on the association between smoking and CKD progression and studies to date have yielded conflicting results. In this prospective cohort study involving Korean CKD patients, smoking was associated with significantly higher risk of worsening kidney function. Furthermore, the risk of adverse kidney outcome was incrementally higher as smoking pack-years were higher. As the duration of smoking cessation increased, the hazard ratios for adverse kidney outcome were attenuated, suggesting that quitting smoking may be a modifiable factor to delay CKD progression.


  • Open Access

    Snoring and incident chronic kidney disease: a community-based prospective cohort study

    by Changhyun Lee, Young Su Joo, Sangmi Lee, Shinchan Kang, Joohwan Kim, Ki Heon Nam, Hae-Ryong Yun, Jong Hyun Jhee, Hyoungnae Kim, Seung Hyeok Han, et al.

    Objectives: Previous studies have shown that symptoms of sleep-disordered breathing are associated with metabolic derangements and vascular disease development. However, the relationship between snoring and renal function is not well investigated. The association between snoring and the development of incident chronic kidney disease (CKD) in subjects with normal renal function was evaluated.Design: Prospective cohort study.Setting: Ansung (rural community) and Ansan (urban community) cities.Participants: Community-based cohort participants aged 40–69 years.Methods: A total of 9062 participants in the Ansung–Ansan cohort study were prospectively followed up from 2001 to 2014. The participants were classified into three groups: non-snorer, 2during the follow-up period.Primary outcome: Incident CKD.Results: The mean subject age was 52.0±8.9 years, and 4372 (48.2%) subjects were male. The non-snorer,<1 day/week and ≥1 day/week groups included 3493 (38.5%), 3749 (41.4%), and 1820 (20.1%) subjects, respectively. Metabolic syndrome was more prevalent in the snoring groups than in the non-snoring group. Snoring frequency showed a significant positive relationship with age, waist:hip ratio, fasting glucose, total cholesterol (Tchol) and low-density lipoprotein cholesterol. During a mean follow-up of 8.9 years, 764 (8.4%) subjects developed CKD. Cox proportional hazards model analysis revealed that the risk of CKD development was significantly higher in subjects who snored ≥1 day/week than in non-snorers, even after adjustments for confounding factors (HR 1.23, 95% CI 1.09 to 1.38, p<0.01).Conclusion: Snoring may increase the risk of CKD development in subjects with normal renal function.


  • Open Access

    Framingham risk score and risk of incident chronic kidney disease: A community-based prospective cohort study

    by Changhyun Lee, Hae-Ryong Yun, Young Su Joo, Sangmi Lee, Joohwan Kim, Ki Heon Nam, Jong Hyun Jhee, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, et al.

    Changhyun Lee, Hae-Ryong Yun, Young Su Joo, Sangmi Lee, Joohwan Kim, Ki Heon Nam, Jong Hyun Jhee, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Seung Hyeok Han. Kidney Research and Clinical Practice 2019;38:49-59. https://doi.org/10.23876/j.krcp.18.0118